<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890435</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL08N1</org_study_id>
    <secondary_id>COG-ADVL08N1</secondary_id>
    <secondary_id>NCI-08-C-0223</secondary_id>
    <secondary_id>CDR0000616064</secondary_id>
    <nct_id>NCT00890435</nct_id>
  </id_info>
  <brief_title>Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial</brief_title>
  <official_title>A Pharmacokinetic Participation Questionnaire Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about why patients or their guardians agree or decline to
      participate in the optional pharmacokinetic portion of a phase I treatment study may help
      doctors plan clinical trials in the future.

      PURPOSE: This clinical trial is looking at decision making about participating in
      pharmacokinetic studies in patients enrolled in a phase I treatment clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To use a simple 2-page survey to gather preliminary information on why patients or
           parents/guardians (if patient is a minor) do or do not agree to participate in the
           optional pharmacokinetic portion of a phase I treatment study while consenting to
           participate in the phase I treatment study.

      OUTLINE: This is a multicenter study.

      Patients or parents/guardians (if patient is a minor) complete a short questionnaire on the
      reasons for agreeing/declining to participation in the optional pharmacokinetic sampling
      component of the phase I clinical trial.

      Patient demographics and other relevant information are collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between study questionnaire answers and patient demographics</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between study questionnaire answers and time required by pharmacokinetic sampling</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between study questionnaire answers and the need for additional IV</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Leukemia</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A patient (family) who has consented to participate in a Phase I trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patients or their parents/guardians (if patient is a minor) consented to participate
             in a phase I treatment clinical trial with an optional pharmacokinetic (PK) component,
             within the past 4 weeks

               -  Must not have withdrawn consent for the phase I treatment study

                    -  Patients or their parents/guardians are eligible regardless of whether they
                       initially agreed to participate in the PK sampling

                         -  Must not withdraw consent for PK sampling prior to completing the study
                            questionnaire if initially agreed to optional PK sampling

                    -  Patients or their parents/guardians are eligible regardless of whether they
                       actually completed PK sampling (provided reasons for not completing the
                       sampling was not withdrawal of the initial consent to the phase I treatment
                       study)

        PATIENT CHARACTERISTICS:

          -  Not cognitively or physically impaired

          -  May participate no more than once in the study questionnaire survey

        PRIOR CONCURRENT THERAPY:

          -  No limit on participation in the number of prior phase I trials or other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Fox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood ependymoblastoma</keyword>
  <keyword>childhood medulloepithelioma</keyword>
  <keyword>childhood meningioma</keyword>
  <keyword>childhood mixed glioma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>adult astrocytic tumors</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>adult ependymal tumors</keyword>
  <keyword>adult meningeal tumor</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult oligodendroglial tumors</keyword>
  <keyword>adult pineal parenchymal tumor</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>mast cell leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

